A recent case–control study suggested that DCIS cases with triple positive for p16, COX-2, and Ki67 had a significantly higher rate of progression to invasive breast cancer than those of negative for these biomarkers (8-year risks of subsequent invasive cancer 19.6% and 4.1%, respectively) [39]. The gene discussed is MKI67; the disease is ductal breast carcinoma in situ.